| Literature DB >> 31646087 |
Jenny Sprooten1, Jolien Ceusters2, An Coosemans2,3, Patrizia Agostinis1,4, Steven De Vleeschouwer5,6, Laurence Zitvogel7,8,9,10, Guido Kroemer11,12,13,14,15, Lorenzo Galluzzi16,17,18,19, Abhishek D Garg1.
Abstract
Dendritic- cells (DCs) have received considerable attention as potential targets for the development of anticancer vaccines. DC-based anticancer vaccination relies on patient-derived DCs pulsed with a source of tumor-associated antigens (TAAs) in the context of standardized maturation-cocktails, followed by their reinfusion. Extensive evidence has confirmed that DC-based vaccines can generate TAA-specific, cytotoxic T cells. Nonetheless, clinical efficacy of DC-based vaccines remains suboptimal, reflecting the widespread immunosuppression within tumors. Thus, clinical interest is being refocused on DC-based vaccines as combinatorial partners for T cell-targeting immunotherapies. Here, we summarize the most recent preclinical/clinical development of anticancer DC vaccination and discuss future perspectives for DC-based vaccines in immuno-oncology.Entities:
Keywords: Antigen cross-presentation; DAMPs; TLR signaling; clinical trial; immune checkpoint blockers; plasmacytoid dendritic cells; tumor-infiltrating lymphocytes
Year: 2019 PMID： 31646087 PMCID： PMC6791419 DOI： 10.1080/2162402X.2019.1638212
Source DB: PubMed Journal: Oncoimmunology ISSN： 2162-4011 Impact factor: 8.110